{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:04:47Z","timestamp":1781625887880,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PSMA PET\/CT (Prostate-specific membrane antigen positron emission tomography \/ computed tomography) has revolutionized prostate cancer imaging. While PSMA expression is influenced by androgen receptor pathway inhibitors (ARPI), few studies have examined the specific effects of apalutamide, a widely used ARPI for hormone-sensitive metastatic prostate cancer. This study evaluated the impact of apalutamide on PSMA radioligand uptake.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We evaluated 17 patients with metastatic hormone-sensitive prostate cancer (mHSPC) who underwent [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA-1007 PET\/CT imaging prior to (PET1) (time from PET1 to initiation of apalutamide: 0.40 months; range 0.03\u20135.90 months) and during apalutamide treatment (PET2) (time from apalutamide initiation to PET2: 5.30 months; range 1.70\u201320.30 months). Biodistribution and tumor uptake were calculated using whole body total tumor volume (TTV), TTV-SUV\n                      <jats:sub>max<\/jats:sub>\n                      and TTV-SUV\n                      <jats:sub>mean<\/jats:sub>\n                      and changes between imaging time points were analysed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All patients demonstrated significant clinical and biochemical PSA responses after treatment initiation (median PSA (ng\/mL) 46.40 vs. 0.03,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). On PSMA PET\/CT during apalutamide therapy, patients showed an overall decrease in TTV-SUV\n                      <jats:sub>max<\/jats:sub>\n                      , TTV-SUV\n                      <jats:sub>mean<\/jats:sub>\n                      and TTV. Median decreases in TTV-SUV\n                      <jats:sub>max<\/jats:sub>\n                      and TTV-SUV\n                      <jats:sub>mean<\/jats:sub>\n                      were \u2212\u200954% and \u2212\u200928%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.020). TTV exhibited a significant median decrease by -53% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). In 4\/17 (23.5%) patients imaging and biochemical response revealed discordant results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This pilot study indicates that, in mHSPC patients, PSMA upregulation is unlikely with intermediate to long-term apalutamide therapy. However, an increase of imaging parameters with synchronous decrease of PSA levels should raise suspicion of early imaging progression, resulting in close monitoring. Further research is warranted to explore early treatment response in the hormone-sensitive stadium.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-025-00965-y","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:15:03Z","timestamp":1765041303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA expression assessed by [18F]PSMA-1007 PET\/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamide"],"prefix":"10.1186","volume":"25","author":[{"given":"Elena Katharina","family":"Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie Carina","family":"Kunte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Zahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can Daniel","family":"Aydogdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Peter","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennert","family":"Eismann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Rodler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf Alexander","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Georg","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena Maria","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"965_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.6004\/jadpro.2019.10.5.8","volume":"10","author":"UJ Patel","year":"2019","unstructured":"Patel UJ, Caulfield S. Apalutamide for the treatment of nonmetastatic Castration-Resistant prostate cancer. J Adv Pract Oncol. 2019;10:501\u20137. https:\/\/doi.org\/10.6004\/jadpro.2019.10.5.8.","journal-title":"J Adv Pract Oncol"},{"key":"965_CR2","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Ju\u00e1rez A, Merseburger AS, \u00d6zg\u00fcro\u011flu M, Uemura H, Ye D, Brookman-May S, Mundle SD, McCarthy SA, Larsen JS, Sun W, Bevans KB, Zhang K, Bandyopadhyay N, Agarwal N. Apalutamide in patients with metastatic Castration-Sensitive prostate cancer: final survival analysis of the Randomized, Double-Blind, phase III TITAN study. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39:2294\u2013303. https:\/\/doi.org\/10.1200\/JCO.20.03488.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"965_CR3","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong L-M, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet (London England). 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet (London England)"},{"key":"965_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2967\/jnumed.108.057307.From","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. Response criteria in solid tumors. J Nucl Med. 2009;50:122\u201350. https:\/\/doi.org\/10.2967\/jnumed.108.057307.From.","journal-title":"J Nucl Med"},{"key":"965_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Calais J, Rettig M, Eiber M, Weber M, Benz MR, Farolfi A. Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic Castration-resistant prostate cancer. Radiology. 2023;308:1\u201312. https:\/\/doi.org\/10.1148\/radiol.222148.","journal-title":"Radiology"},{"key":"965_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/JU.0000000000002326","volume":"207","author":"O Sartor","year":"2022","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Perez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ. Re: Lutetium-177-PSMA-617 for metastatic Castration-Resistant prostate cancer. J Urol. 2022;207:467\u20138. https:\/\/doi.org\/10.1097\/JU.0000000000002326.","journal-title":"J Urol"},{"key":"965_CR7","doi-asserted-by":"publisher","unstructured":"Bakht MK, Oh SW, Youn H, Cheon GJ, Kwak C, Kang KW. Influence of androgen deprivation therapy on the uptake of PSMA-targeted agents: emerging opportunities and challenges. Nucl Med Mol Imaging. 2010. 2017;51:202\u2013211. https:\/\/doi.org\/10.1007\/s13139-016-0439-4","DOI":"10.1007\/s13139-016-0439-4"},{"key":"965_CR8","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1073\/pnas.1106383108","volume":"108","author":"MJ Evans","year":"2011","unstructured":"Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA. 2011;108:9578\u201382. https:\/\/doi.org\/10.1073\/pnas.1106383108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"965_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22147431","volume":"22","author":"M Staniszewska","year":"2021","unstructured":"Staniszewska M, Fragoso Costa P, Eiber M, Klose JM, Wosniack J, Reis H, Szarvas T, Hadaschik B, L\u00fcckerath K, Herrmann K, Fendler WP, Iking J. Enzalutamide enhances Psma expression of Psma-low prostate cancer. Int J Mol Sci. 2021;22:1\u201312. https:\/\/doi.org\/10.3390\/ijms22147431.","journal-title":"Int J Mol Sci"},{"key":"965_CR10","doi-asserted-by":"publisher","unstructured":"Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, Drakaki A, Grogan T, Rettig MB, Czernin J, Calais J. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023;13. https:\/\/doi.org\/10.1186\/s13550-023-01048-4.","DOI":"10.1186\/s13550-023-01048-4"},{"key":"965_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41824-023-00178-1","volume":"7","author":"V Murthy","year":"2023","unstructured":"Murthy V, Appiah-Kubi E, Nguyen K, Thin P, Hotta M, Shen J, Drakaki A, Rettig M, Gafita A, Calais J, Sonni I. Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. Eur J Hybrid Imaging. 2023;7:1\u201313. https:\/\/doi.org\/10.1186\/s41824-023-00178-1.","journal-title":"Eur J Hybrid Imaging"},{"key":"965_CR12","doi-asserted-by":"publisher","unstructured":"Rosar F, Neher R, Burgard C, Linxweiler J, Schreckenberger M, Hoffmann MA, Bartholom\u00e4 M, Khreish F, Ezziddin S. Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14071696.","DOI":"10.3390\/cancers14071696"},{"key":"965_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","volume":"47","author":"S Vaz","year":"2020","unstructured":"Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:9\u201315. https:\/\/doi.org\/10.1007\/s00259-019-04529-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"965_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","volume":"1","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway Blockade in metastatic prostate cancer. Eur Urol Oncol. 2018;1:78\u201382. https:\/\/doi.org\/10.1016\/j.euo.2018.03.010.","journal-title":"Eur Urol Oncol"},{"key":"965_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 Chaarted trial. J Clin Oncol. 2018;36:1080\u20137. https:\/\/doi.org\/10.1200\/JCO.2017.75.3657.","journal-title":"J Clin Oncol"},{"key":"965_CR16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, \u00d6zg\u00fcro\u011flu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686\u2013700. https:\/\/doi.org\/10.1016\/S1470-2045(19)30082-8.","journal-title":"Lancet Oncol"},{"key":"965_CR17","doi-asserted-by":"publisher","unstructured":"Hober\u00fcck S, L\u00f6ck S, Winzer R, Z\u00f6phel K, Froehner M, Fedders D, Kotzerke J, H\u00f6lscher T. 68Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI Res. 2020;10. https:\/\/doi.org\/10.1186\/s13550-020-00723-0.","DOI":"10.1186\/s13550-020-00723-0"},{"key":"965_CR18","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","volume":"60","author":"L Emmett","year":"2019","unstructured":"Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, Nguyen Q, Hickey A, Ihsheish N, O\u2019Neill G, Horvath L, Chalasani V, Stricker P, Joshua AM. Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen Blockade. J Nucl Med. 2019;60:950\u20134. https:\/\/doi.org\/10.2967\/jnumed.118.223099.","journal-title":"J Nucl Med"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00965-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00965-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00965-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:06:51Z","timestamp":1781622411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-025-00965-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00965-y","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Medical Faculty of LMU Munich (# 19\u20130942). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a0\n                      \n                      ,\n                      \n                      ,\n                      \n                      and\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}